Stock XLO XILIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.09 USD +7.92% Intraday chart for Xilio Therapeutics, Inc. -5.22% +98.18%
Apr. 19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
Apr. 01 Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Evolution of the average Target Price on Xilio Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

31fdc2930fec6bb23324ba3.9ovZpj2_uHsVGxq8uBqQQ75yCe7MurT-hOX5O1t4yEI.w8O1lVvu3SN6eljsiyvaCOcUVqST_9mnyNa7cDAylzXG5bH0T-rCFHJWTw~a9af5390f4de8f8de7e09c370f6629f4

Analyst Recommendations on Xilio Therapeutics, Inc.

Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating MT
Chardan Initiates Xilio Therapeutics With Buy Rating, $7 Price Target MT
Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating MT
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating MT
HC Wainwright Starts Xilio Therapeutics at Buy with $36 Price Target MT
Guggenheim Starts Xilio Therapeutics at Buy With $40 Price Target MT
Morgan Stanley Starts Xilio Therapeutics at Overweight With $32 Price Target MT
Raymond James Starts Xilio Therapeutics at Outperform With $31 Price Target MT
Cowen Starts Xilio Therapeutics at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.09 USD
Average target price
4.667 USD
Spread / Average Target
+328.13%
High Price Target
6 USD
Spread / Highest target
+450.46%
Low Price Target
3 USD
Spread / Lowest Target
+175.23%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Xilio Therapeutics, Inc.

Morgan Stanley
Chardan Research
Raymond James
HC Wainwright
Cowen
Guggenheim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. XLO Stock
  4. Consensus Xilio Therapeutics, Inc.